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Abstract
Background: The federal state of Hesse, Germany, introduced a laboratory-based reporting scheme for
carbapenem-resistant organisms (CROs).
Method: The results of the first year of mandated reporting of CROs from April 2012 through March 2013 to the
Public Health Authority of Frankfurt/Main, responsible for a population of 700,000 inhabitants, are described.
Results: Within a period of 12 months 243 CROs were notified to the health authority. Of these 213 isolates had
been reported from 16 of the 17 hospitals in Frankfurt/Main, 6 from ambulatory settings and 24 from clinics outside
of Frankfurt/Main. Mean incidence rate per 1,000 patient days in hospitals was 0.138 (range 0.02-0.28).
Conclusion: In Frankfurt/Main almost all hospitals have reported CROs in the study period though the frequency of
isolation varies strongly and many facilities only report CROs sporadically. Molecular data indicate a high diversity of
different carbapenemases. Autochthonous transmission must be assumed despite the absence of major outbreaks.
Rapid and coordinated efforts by clinicians and health departments are crucial to control the spread of CRO infections.
The mandatory reporting scheme provides important data to guide the implementation of preventive measures.
Keywords: Gram-negative bacteria, Multidrug resistance, Carbapenemase, Mandatory reporting, Epidemiology,
Population-based surveillance
Background
For nearly 20 years carbapenems had retained almost
universal activity against Enterobacteriaceae [1], but in
recent years resistance is accumulating globally. The
current increased use of carbapenems is a consequence
of the growing prevalence of cephalosporin-resistant
pathogens. This cycle of increased antimicrobial usage
and escalating resistance leads to an inevitable tension
between the good of the individual patient and that of
public health. Furthermore the applicability of this indis-
pensable group of second-line antibiotics is jeopardized.
Increasing prevalence of carbapenem-resistant organisms
(CROs) in healthcare facilities has been reported not only
from Asia, but also from the USA and Europe [2-5].
First reports of outbreaks due to carbapenem-resistant
Enterobacteriaceae (CRE) in Germany, particularly those
producing Klebsiella pneumoniae carbapenemase (KPC)
have been published [6,7] in 2009. Carbapenem-resistance
can be conferred by the presence of various mechanisms
of resistance. The currently most significant develop-
ment is the world-wide spread of carbapenemases, beta-
lactamases capable of hydrolysing most beta-lactams,
including carbapenems. Carbapenemases such as OXA-48,
KPC- and VIM-type carbapenemases are the most preva-
lent in Germany [8]. Furthermore, the number of NDM-
type carbapenemases are increasing slowly, with recent
reports of travel-related cases, autochthonous cases and
outbreaks [9,10].
Whereas 13 European countries have included
carbapenem-resistant organisms (CROs) in their list of
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mandatorily notifiable entities in recent years, no report-
ing obligation has been introduced at national level in
Germany to date [11]. Federal states in Germany, how-
ever, may mandate reporting of specified conditions
by local state law. Hesse, one of the federal states of
Germany, was the first federal state to introduce a
mandatory reporting scheme for carbapenem-resistant
gram-negative pathogens in November 2011 [12]. Detailed
reporting criteria (Table 1) were issued in a separate decree
which came into effect in April 2012.
Here we present the results of the first year of mandatory
reporting of CROs in Frankfurt/Main and the Rhine-Main
Region.
Methods
The introduction of the new reporting scheme obliged
laboratories in the federal state of Hesse to report by fax
every detection of a carbapenem-resistant gram-negative
organism (according to the criteria listed in Table 1)
within 24 hours directly to the local health authority in
charge. The results presented in this report include all
notifications received by the public health authority of
Frankfurt/Main from April 2012 (the introduction of de-
tailed reporting criteria) through March 2013. These in-
clude notifications from all patients treated in Frankfurt’s
health care facilities as well as notifications of the city’s
residents treated in health care facilities outside of the
city of Frankfurt/Main. Frankfurt/Main represents a typ-
ical city at the heart of a large metropolitan area concen-
trating highly specialized health care facilities within the
region. By number Frankfurt holds 10% of the hospitals
in the federal state of Hesse (17/172), yet these include a
number of large tertiary care hospitals whose catchment
areas reach far beyond the city’s boundaries. The
city’s 700,000 inhabitants represent 12% of the federal
states population (6.1 million). Its hospitals provide
6,240 beds (17.2% of beds provided by the state) or
1,594,388 bed days (15.7%) compared to 36,229 beds
or 10,179,034 bed days state wide. Published results of the
mandated reporting of CRO’s in Hesse display a total of
549 notifications between January 2012 and April 2013 at
state level compared to 252 (23.1%) notifications (these
include 219 notifications from Frankfurt/Main in the study
period of this publication + 33 notifications from Jan 2012
through Mar 2012) for Frankfurt/Main [13].
Upon receipt lab reports were reviewed by the health
authority. Additional clinical information was requested
from the treating physician. On identification of possible
clusters individual cases were followed up by contacting
the hygiene staff of the concerned facilities by phone. If ne-
cessary infection control measures were recommended.
Reports were saved in an Excel file and included the
following information: ID; name of patient, date of birth,
sex, place of residence, date of hospitalization, infection/
colonisation status, sampling date, previous hospitali-
zations and travel history, isolation precautions, genus
and species of the detected organism, susceptibility pro-
file and if applicable also the result of carbapenemase
testing. Calculations were performed with SPSS version
15 software.
The number of total patient days required for the cal-
culation of the incidence was provided on a quarterly
basis by the participating hospitals.
Every notification of a pathogen not previously re-
ported for the patient was counted as a case. Since more
than one resistant pathogen was identified for several
patients, the number of cases exceeded the number of
patients.
Ethical approval was not required for this descriptive
study as the information presented is based exclusively
on anonymized data from legally mandated public health
surveillance and contains no direct or indirect person
identifiers.
Table 1 Reporting criteria for gram-negative bacteria,
Hesse, Germany
1. Every detection of a carbapenemase by molecular methodology1
2. Phenotypic resistance tests (culture + antibiogram)
a) Pseudomonas aeruginosa
If resistant to all three of the following antibiotics:
Imipenem, meropenem and ceftazidime
b) Enterobacteriaceae (if not mentioned elsewhere)
If resistant to at least one of the following antibiotics:





In case of resistance to imipenem and resistance to ertapenem or
meropenem (an isolated increase of the MIC for imipenem together
with normal MICs for meropenem and – if performed – for ertapenem




In case of resistance to imipenem or meropenem. (isolated resistance to
ertapenem does not require reporting)






1Laboratories are encouraged but not obliged to type carbapenem-resistant
bacteria, analyses are offered free of charge by the national reference centre.
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Results
From April 2012 through March 2013 the Public Health
Authority of Frankfurt/Main received reports of 243
multidrug-resistant gram-negative organisms identified
according to the reporting criteria from 225 patients:
these included 30 isolates in the second quarter of 2012,
70 in the third, 73 in the fourth quarter of 2012 and 70
in the first quarter of 2013 (Figure 1). P. aeruginosa was
the most frequently notified species (153), followed by
K. pneumoniae (33), A. baumannii (28), E. coli (13),
Enterobacter spp. (12) and other enterobacteriaceae (4)
with carbapenem-resistance. The identification of a carba-
penemase was reported for 32 pathogens (Table 2). The
total number of tests performed to identify carbapene-
mases is not known.
The Public Health Authority received notifications for
213 CROs from 16 of the 17 hospitals in Frankfurt/Main, 6
reports were from outpatient facilities in Frankfurt/Main
and 24 notifications came from hospitals outside of city,
for patients under the responsibility of the Frankfurt City
Public Health Authority, due to their registered place
of residence. While 48% of the notifications originated
from a single tertiary care hospital (103 notifications,
0.28/1,000 patient days), the other hospitals notified 22
(0.20/1,000 patient days), 18 (0.19/1,000 patient days),
14 (0.09/1,000 patient days), two hospitals notified 13
(0.13 and 0.06/1,000 patient days), 1 × 8 (0.15/1,000
patient days), 1 × 6 (0.11/1,000 patient days), 1 × 4
(0.04/1,000 patient days), 1 × 3 (0.05/1,000 patient days),
3 × 2 (0.03, 0.05, 0.05/1,000 patient days), 3 × 1 isolates
(0.02, 0.02, 0.05/1,000 patient days) respectively. The
absolute frequency given above does not reflect the size
and occupancy of the hospital and is better expressed
by the yearly incidence/1,000 patient days (given in
parentheses). The average yearly incidence was 0.138
notifications/1,000 patient days. 67% of the notifications
concerned isolates from male patients. Regarding the
patients from outpatient facilities, all patients had their
place of residence in Germany, 5 in Frankfurt/Main, 1 in a
neighbouring district in Hesse, none reported prior
hospitalization, 1 reported previous travel abroad (Serbia), 5
were colonized 1 infected with a CRO and 3 were carriers
of an identified carbapenemase (VIM-2, OXA-23-like
carbapenemase, unspecified metallo-carbapenemase). The
average age of the patients was 60 ± 20 years ranging from
0–97 years. 45% of the notified patients had their main
residence in Frankfurt/Main, 28% were residents of the
Rhine-Main region (bordering to the city of Frankfurt/
Main) and a further 18% were German residents outside of
the Rhine-Main region. 9% of patients had their place of
residence abroad. Thirty-two patients (13% of all patients)
had received healthcare in a foreign country (Table 2).
Two-thirds of the isolated pathogens were reported as
colonizers, 30% as causative agent of infections. One
third (34%) of all isolates originated from sputum or tra-
cheal aspirates, 23% from wound swabs, 18% from skin
or perineal swabs, 17% from urine samples, 3% from
blood cultures and 5% from other materials.
No significant differences were observed with regard
to age, sex and history of previous hospitalization be-
tween different species. However, the sampling sites
from which the different pathogens were isolated were
highly diverse. P. aeruginosa was isolated most frequently
from tracheal aspirates (46%), A. baumannii from wound
swabs (46%) and Enterobacter spp. from skin or perineal
swabs (27%) (Figure 2).
Figure 1 Notifications of CROs – Frankfurt/Main, 1.4.2012-31.3.2013.
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Twenty-six per cent of the samples had been taken
within the first two days of hospitalization and 22% of
the CROs had been detected after having been hospital-
ized for more than a month.
Discussion
Carbapenem-resistant pathogens are an increasing threat
world-wide, in Europe [14] and also in Germany [8,15].
In 2010 Grundmann et al. proposed a five-level staging
system to index the magnitude of carbapenem-non-
susceptibility across Europe. Germany was categorized into
level 3 indicating regional spread together with Hungary
and France. Only Italy, Poland (level 4), Greece and Israel
(level 5) were categorized into higher levels [16]. According
to this staging scheme, a group of European experts reas-
sessed the situation in 2013. Germany remained in the
Table 2 Demographic characteristics and history of hospitalization abroad of patients colonized or infected with CRO,
Frankfurt/Main, 1.4.2012- 31.03.2013
Total P. aeruginosa A. baumannii K. pneumoniae E. coli Enterobacter
Total 243a 153 28 33 13 12
Age (years) (mean) 58.9 ± 20.1 59.5 ± 19.7 53.1 ± 17.2 59.4 ± 19.5 59.2 ± 23.3 58,0 ± 30,7
Age range (years) 0-97 0-97 18-84 0-90 2-91 0-89
Percentage of male patients 66.7 60.1 82.1 81.8 61.5 83.3
Hospitalization abroad during
previous 6 months
32 patientsb N = 10 N = 11 N = 7 N = 2 N = 1
Iran Egypt Egypt Qatar Sri Lanka
Kuwait Brasil Greece India
Brasil Ukraine Nicaragua
Qatar Qatar Italy




Russia (n = 2)
Macedonia Turkey
Morocco
Place of residence abroad N = 21 (8.6%) N = 11 N = 6 N = 2 N = 2
Egypt Algeria Egypt India
Iran Egypt India Egypt
India Qatar
Kuwait Kuwait
Macedonia Russia (n = 2)





Infection (%) 29.7 24.2 28.6 30.3 23.1 50.0
Carbapenemase (cases) 32 casesc Metallo-ß-lactamase,
unspecified (n = 3)
OXA-23-like (n = 7) OXA-23-like (n = 1) OXA-48 (n = 4)
VIM-1 (n = 1) NDM-1 (n = 1) OXA-48 (n = 4) NDM-7 (n = 1)
VIM-2 (n = 3) NDM, not further
specified (n = 3)
KPC-2 (n = 1)
KPC-3 (n = 1)
aincluding C. koseri, E. sakazakii. 1 K. oxytoca, P mirabilis.
bincluding 1 patient, C. koseri Libya.
cincluding OXA-48 (n = 1) from C. koseri; NDM1/6 (n = 1) from K. oxytoca.
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category 3 - together with France, Croatia, Kosovo, United
Kingdom, Spain, and Poland, whereas meanwhile three
countries (Hungary, Israel, and Ireland) had been catego-
rized in stage 4, and three other countries (Greece, Italy
and Malta) in category 5 [11].
In Frankfurt/Main CROs had already been reported
sporadically and sent to reference laboratories in previ-
ous years on the basis of a general clause in the German
Protection against Infection Act requiring notification of
any cluster of nosocomial infections which may consti-
tute an outbreak of public health relevance. The first no-
tifications of CROs to the Frankfurt City Public Health
Authority were received in the years 2005 to 2007 primar-
ily reporting outbreaks with A. baumannii in Frankfurt
hospitals [17]. In 2007 an A. baumannii producing the
New Delhi metallo-β-lactamase-1 (NDM-1) had been iso-
lated for the first time in Frankfurt/Main from a patient
who had been repatriated to Germany from Serbia [18,19].
With the obligation to report carbapenem-resistant organ-
isms in the federal state of Hesse, the availability and qual-
ity of data have improved considerably, particularly as all
laboratories are obliged to follow these regulations, includ-
ing hospital-based and outpatient laboratory facilities. The
detection of these organisms is however influenced by the
quality and frequency of clinical microbiological analyses
and screening schemes, as well as by case-mix of the med-
ical institutions in which the samples have been drawn.
Therefore, an interpretation based on the number of pa-
tients or on incidence rates must be done carefully, and
the possibility of inter-facility comparison is limited.
Within the first year of mandatory reporting the
Frankfurt City Public Health Authority received 243 no-
tifications of CROs. Carbapenem-resistant gram-negative
organisms were reported from nearly all inpatient facilities
and also a few outpatient facilities in Frankfurt/Main.
Thus, carbapenem-resistance is not solely a problem con-
fined to a few highly specialized hospitals. The problem
has meanwhile reached all healthcare facilities, even
though cases are distributed disproportionately and 48%
of all notifications were received from a single hospital
which however reported only 23% of the total of patient
days registered for Frankfurt’s healthcare facilities. A pos-
sible explanation for such high incidences in some of the
facilities is that these are large tertiary care clinics some
of which treat a relatively high proportion of patients in
intensive care units and other large highly specialized
treatment units. Many of the patients treated here are
immunocompromised and highly susceptible to bac-
terial infections. The widespread presence of CROs in
Frankfurt’s hospitals points towards autochthonous trans-
missions in the region. Yet large inter-institutional out-
breaks have not been reported and similarly investigations
performed by the local health authority gave no indication
of such events. None of the patients treated in the out-
patient facilities reported a history of prior hospitalization.
This may be an indication of ongoing community trans-
mission. Though the number of reported carbapenemases
may not reflect their true prevalence, the results of those
identified and reported indicate a high diversity of differ-
ent carbapenemases in the region (Table 2).
30% of the notifications reflected infections with
carbapenem-resistant organisms, of which 31% were
wound-, 23% urinary tract-, 19% respiratory tract-
infections and 11% bloodstream infections. 71% of the pa-
tients with CROs had a history of hospitalization within
the previous 6 months indicating that prior hospitalization
Figure 2 Notified CROs by species and sampling site, Frankfurt/Main, 1.3.2012-31.4.2013.
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can serve as a risk factor for the carriage of CROs.
Furthermore 21 of these notifications (8.6%) related to
patients who had previously been treated in hospitals
abroad, in countries or regions with a known high preva-
lence of CROs. Several of the patients had been transferred
directly from hospitals abroad for specialised treatment
into medical facilities in Frankfurt/Main. This may be an
indication of a substantial cross-border transfer of medical
patients.
26% of the notifications were related to patients who
had been hospitalized less than 48 hours. The occur-
rence of CROs in patients who have only recently been
admitted to the hospitals may be an indication of an ac-
quisition of the pathogen in the community setting or
by undiagnosed acquisition in another previously visited
health care institution.
For several of the patients reported here, the carrier
status for CRO was known on admission so that these
patients were isolated pre-emptively, as suggested in the
latest recommendations of the German Commission for
Hospital Hygiene and Infectious Disease Prevention
published in October 2012 [20]. The other patients with
carbapenem-resistant organisms were isolated only after
laboratory findings had been communicated and a few
of these patients had already been dismissed when the in-
formation became available, so that a transfer of the CROs
to further patients could not be excluded with certainty.
In two cases for which a transmission of the pathogen was
suspected, extensive contact tracing and environmental in-
vestigations were performed, ending with negative results.
These patients were colonized with Klebsiella spp. both
carrying an NDM-type carbapenemase.
The CDC guidance for control of carbapenem-resistant
enterobacteriaceae (CRE) recommends different prevention
strategies, depending on the prevalence of CRE within a
region [21]. Regions with few CRE identified are defined as
those where the majority of healthcare facilities do not
regularly have patients with CRE admitted. This includes
regions where some facilities may have several CRE colo-
nized or infected patients but are surrounded by facilities
with only a few (e.g. less than one per month) or none. This
situation is applicable to Frankfurt/Main in 2012/2013.
CDC recommends aggressive measures to control the
problem in regions with few CRE identified by making
CRE a reportable event, closely monitoring the situation
including periodically surveying acute and long-term
care facilities for the presence of CRE and providing
feedback of the results of the data analysis to the facil-
ities. An important aspect is the identification of facil-
ities with high CRE prevalence and communication of
this information to other facilities. Furthermore, health
departments should cooperate closely with infection pre-
vention personnel, monitor implementation of prevent-
ive measures in facilities with CRE and provide training
and timely information to facilities that have so far not
identified CRE patients. Finally the inter-facility commu-
nication of CRE findings needs to be encouraged.
Some of these aspects have already been implemented
in Hesse and the Rhine-Main region. CROs have been
made a reportable event in the federal state of Hesse.
The Hessian Hygiene Act 2011 [22] explicitly requires
healthcare facilities which transfer patients to other facil-
ities to inform these about possible CRE findings. How-
ever, to date this has not been consistently implemented.
A local network of medical and nursing professionals
(MRE-Net Rhine-Main) has offered several trainings in
2012 covering the topic of multidrug-resistant gram-
negative pathogens following the publication of the latest
recommendations of the German Commission for Hospital
Hygiene and Infectious Disease Prevention. Further work
is necessary to improve the inter-facility communication
on carriage of multidrug-resistant pathogens.
Data of current regional surveys are available. In May
2012 > 1,000 ambulatory dialysis patients were screened
for multidrug-resistant pathogens by two cooperating
local professional networks (MRSAar-Net and MRE-Net
Rhine-Main) and these included 751 patients from the
Rhine-Main region. Forty of these patients (7.5%) were
colonized with ESBL but all were carbapenem-sensitive.
In November 2012, however, the first two patients with
CROs from an outpatient dialysis facility in Frankfurt
were identified that had been notified according to the
new mandate to report CROs in Hesse. Both were colo-
nized with a carbapenem-resistant K. pneumoniae, one
of which carried an OXA-23-like carbapenemase. In au-
tumn 2012 a total of 150 residents out of 8 of 40 nursing
homes for the elderly in Frankfurt/Main were screened
for multidrug-resistant pathogens. ESBL were identified
in 40 (27%) of the residents, however, no isolate exhib-
ited resistance towards carbapenems.
The new mandate appears to have been rapidly accepted
and implemented successfully within the first four months
(April-July) by laboratories and other health care facilities
in Frankfurt/Main as judged by the number of notifications
which appear to have stabilized after a first sharp increase
and by the predominantly positive feedback received. A
meaningful comparison of the data will however only be
possible after the data have been collected over a longer
period allowing the identification of trends in time.
There are several limitations to this descriptive study
of reporting data. As underreporting is a typical feature
of passive surveillance systems the reported case num-
bers only represent the lowest possible spread of CROs
in the region. Particularly in the beginning of the study
an increase of the reported number of cases could be
observed which most probably corresponds to a brief
period of familiarization with the new reporting obliga-
tion rather than a true increase in the number of cases.
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Furthermore the detail of information which laboratories
and clinicians can be obliged to report will always be
limited within the framework of what can reasonably be
expected in their routine workflow. Details of laboratory
methodology (antibiotic susceptibility testing standards,
selection criteria for typing, typing methodology, pheno-
typic/genotypic test systems, different sensitivity rates)
have not been documented and may vary between differ-
ent laboratories. Finally several factors influencing the
frequency of detection of CROs could not be asked for
such as details on the established screening programs
and the criteria applied in different hospitals, risk factors
for the carriage of CROs such as prior antibiotic treat-
ment and organizational differences between hospitals
including differences in case mix and specialization of
units which may contribute to the differences in the in-
cidence of CROs between the hospitals.
All results from the reporting system, as well as those
from the surveys performed are shared with the health-
care facilities of Frankfurt/Main. Major efforts includ-
ing information events and trainings are being made
in close cooperation with the healthcare facilities aim-
ing to fulfil the hygiene standards and to ensure that
antibiotics are used appropriately in order to minimize
the spread of CROs as effectively as possible. Adequacy
and compliance with established hygiene procedures
and documentation and assessment of CRO findings are
evaluated regularly in the facilities by the health au-
thority. In view of the wide-spread distribution of these
pathogens and the increasing cross-border transfer of
patients, however, a regional approach alone will not be
sufficient.
Conclusions
In Frankfurt/Main most healthcare facilities have re-
ported CROs in the study period. While a few facilities
identified CRO colonized or infected patients regularly
the majority of facilities still encounter CROs on an in-
frequent basis. Although dissemination of CROs mainly
occurs among hospitalized patients there are also indica-
tions of cases in ambulatory settings which could be a
sign of ongoing community transmission. Regarding 243
CROs in twelve months in the Frankfurt/Main metro-
politan area a well-concerted effort is needed to prevent
the further spread of CROs in order to avoid an uncon-
trollable situation as can now be observed worldwide for
ESBL producers. Laboratory capacities for molecular
testing need to be strengthened. The data gathered by
legally mandated reporting of CROs are needed to guide
infection–control measures taken to limit the further
spread of these antibiotic-resistant pathogens. The intro-
duction of a countrywide mandate for reporting would
allow to recognise regional differences and to focus pre-
vention efforts accordingly.
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